



15th Annual Paragraph IV Disputes

Presented by the American Conference Institute (ACI)

April 26–27, 2021

Deepro Mukerjee, national co-chair of Katten's Patent Litigation practice, will participate in "The Economics and Economy of Drug Patents with ACI's Hatch-Waxman Series Advisory Board Members: Optimizing Product Selection, Identifying Targets for Litigation and Monetizing IP Portfolios" breakout session at 3:30 p.m. (ET) on Monday, April 26. The session will focus on:

- Considering the critical factors when selecting products for development:
 - IP constraints and Freedom to Operate
 - Development costs
 - Market forces
 - The potential long-term impact the coronavirus could have on supply chain disruption
- Considering license deals to save litigation spend and remain within budget
- Strengthening your launch strategy
- Examining the value of licensing deals and structures
- Establishing best practices for cost reduction to enhance predictability for cash flow purposes
 - What kind of case management does a client expect with a low budget when there is no settlement?
- Evaluating the impact of the conservation of resources on future investment in research and development

[Learn more about the 15th Annual Paragraph IV Disputes conference.](#)

CONTACTS

For more information, contact your Katten attorney or any of the following attorneys.



Deepro R. Mukerjee

+1.212.940.8552

deepro.mukerjee@katten.com

Attorney advertising. Published as a source of information only. The material contained herein is not to be construed as legal advice or opinion.

©2026 Katten Muchin Rosenman LLP.

All rights reserved. Katten refers to Katten Muchin Rosenman LLP and the affiliated partnership as explained at katten.com/disclaimer.